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Maspin is a serpin that has multiple effects on cell behavior,
including inhibition of migration. How maspin mediates these
diverse effects remains unclear, as it is devoid of protease inhib-
itory activity. We have previously shown that maspin rapidly
inhibits the migration of vascular smooth muscle cells (VSMC),
suggesting the involvement of direct interactions with cell sur-
face proteins. Here, using immunofluorescence microscopy, we
demonstrate that maspin binds specifically to the surface of
VSMC in the dedifferentiated, but not the differentiated, phe-
notype. Ligand blotting of VSMC lysates revealed the presence
of several maspin-binding proteins, with a protein of 150 kDa
differentially expressed between the two VSMC phenotypes.
Western blotting suggested that this proteinwas the1 integrin
subunit, and subsequently both 31 and 51, but not v3,
were shown to associate with maspin by coimmunoprecipita-
tion. Specific binding of these integrins was also observed using
maspin-affinity chromatography, using HT1080 cell lysates.
Direct binding ofmaspin to51was confirmed using a recom-
binant51-Fc fusion protein. Using conformation-dependent
anti-1 antibodies, maspin binding to VSMC was found to lead
to a decrease in the activation status of the integrin. The func-
tional involvement of 51 in mediating the effect of maspin
was established by the inhibition of migration of CHO cells
overexpressing human 5 integrin, but not those lacking 5
expression. Our observations suggest that maspin engages in
specific interactions with a limited number of integrins on
VSMC, leading to their inactivation, and that these interac-
tions are responsible for the effects of maspin in the pericel-
lular environment.
Maspin is a member of the serpin family of serine protease
inhibitors (SERPINB5).2 It was originally identified as a gene
down-regulated in invasive breast cancer and proposed as a
class II tumor suppressor (1), and has since been shown to have
many effects on cellular behavior that are consistent with this
activity. It has been shown to decrease the proliferation, migra-
tion, and metastasis of tumor cells in vivo (1, 2) and their inva-
sion in vitro (3, 4), and to increase apoptosis of endothelial cells
(5) and inhibit angiogenesis (6). However, the cellular effects of
maspin are not restricted to tumor cells, and we have demon-
strated that maspin can inhibit the migration of vascular
smooth muscle cells (7).
VSMCmigration is a key event in the development of ather-
osclerosis (8), and contributes significantly to restenosis after
angioplasty (9) and transplant arteriosclerosis (10). VSMC are
not terminally differentiated and acquire migratory capacity as
part of a phenotypic switch from a contractile, quiescent state
to a dedifferentiated phenotype, characterized by proliferation
and increased extracellular matrix synthesis, in addition to
motility (11). This allows VSMC to respond to environmental
cues following vascular injury. The phenotypic plasticity of
VSMC is regulated by an array of signals, among which inte-
grin-mediated association with surrounding extracellular
matrix and changes in the expression of matrix-degrading pro-
teases are prominent (12–14).
How maspin mediates its various cellular effects is unclear.
Maspin has been reported to be an inhibitor of plasminogen
activation (3, 15, 16), but we have shown that maspin is unable
to inhibit either uPA- or tPA-catalyzed plasminogen activation
under conditions in which the serpin PAI-1 was completely
inhibitory (7). The anti-proteolytic inhibitory mechanism of
serpins is dependent on characteristics of the reactive center
loop (RCL) allowing it to adopt the necessary canonical confor-
mation and rearrangements subsequent to protease binding
(17). The RCL of maspin does not have the required character-
istics (7, 18), and the conclusion thatmaspin is a non-inhibitory
serpin is fully supported by its crystal structure (19, 20).
Another confounding factor in understanding the mecha-
nisms underlying the cellular effects of maspin is that, in com-
monwith the serpin PAI-2, it lacks an authentic secretion signal
sequence. Nevertheless it has been shown to enter secretory
vesicles (21) and is found extracellularly, in the cytoplasm and
also in the nucleus (21, 22). Cytoplasmic and nuclear binding
proteins for maspin have been identified (23–25), and may be
responsible for its effects on proliferation and apoptosis. How
secreted, extracellular maspin exerts its effects is unclear, but a
function as a cell signaling ligand has been proposed (26–28).
However, the characteristics of the maspin inhibitory effect on
VSMC migration point to a more direct effect of maspin.
To determine the mechanism of the maspin effect on VSMC
migration, we have now attempted to identify maspin-binding
proteins on the surface of these cells. In this report we provide
biochemical, cellular, and functional evidence that the effect of
maspin on cell migration is mediated by specific binding to cell
adhesion receptors of the integrin family. We find that maspin
binds specifically to 1 integrins on the surface of dedifferenti-
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ated VSMC, which leads to a reduction in the activation status
of the integrin, and that the binding of maspin to 51 is suffi-
cient for its inhibitory effects on cell migration and may repre-
sent a more general mechanism underlying its diverse biologi-
cal effects.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Proteins—Primary aortic smooth
muscle cells, media, and supplements were from TCS Cell
Works (Buckingham, UK). These cells were routinely main-
tained in the dedifferentiated state in Medium 231 supple-
mented with 4.9% fetal bovine serum, FGF2 (2 ng/ml), EGF
(0.5 ng/ml), heparin (5 ng/ml), insulin (5 g/ml), and BSA (0.2
g/ml). When necessary these cells were differentiated by cul-
turing in Medium 231 supplemented with 1% fetal bovine
serum and heparin (30 g/ml) for 7 days. 5CHO (clone 17)
and B2CHO cell lines were as previously detailed (29) and
HT1080 were obtained from ATCC. These cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM), sup-
plemented with 10% (v/v) fetal calf serum, and 0.1 mM non-
essential amino acids. All cell culture reagents including ECM
components were from Invitrogen (Paisley, UK).
Primary antibodies to maspin were goat polyclonal (R&D
Systems, Abingdon, UK) and mouse monoclonal G167-70
(BD Biosciences, NJ). Monoclonal antibodies to 1 integrin
subunit forWestern blotting and immunoprecipitation were
from AbD Serotec (Oxford, UK) and for immunocytochem-
istry from Fedor Beditchevski (University of Birmingham).
3 and 5 monoclonal antibodies were fromMillipore (Dan-
vers, MA). v antibodies for immunocytochemistry (L230)
were a gift from Celltech (Slough, UK), for Western blotting
and immunoprecipitation from R&D Systems, and function
blocking (MAB1980) from Millipore. Monoclonal antibodies
12G10 andmAb13were fromMartinHumphries (University of
Manchester, UK). Polyclonal anti-3 integrin was kindly pro-
vided by Barry Coller (Rockefeller University, New York). The
monoclonal antibodies to uPA (clone 5) and uPAR (R4) were
kindly provided by Gunilla Høyer-Hansen (Finsen Laboratory,
Copenhagen). Polyclonal anti-GAPDHwas fromCell Signaling
Technology (Danvers, MA). Secondary antibodies were from
Dako (Ely, UK) and Invitrogen.
Recombinant maspin, expressed in Saccharomyces cerevi-
siae, was as previously described (7). Recombinant 51-Fc
integrin, which is the ectodomain of51 integrin expressed as
a fusion protein with mutated human 1 Fc domains to pro-
mote heterodimer formation, was kindly provided by Martin
Humphries (University of Manchester) (30).
Immunoprecipitation, Western, and Ligand Blotting—Cell
lysates were prepared by washing subconfluent monolayers
twice with PBS prior to harvesting in PBS containing complete
EDTA-free inhibitors (Roche Applied Science, Burgess Hill,
UK). Cells were lysed at 5 107 cell/ml in 50mMHepes pH 7.8,
150 mM NaCl containing 1% (v/v) Triton X-100 and protease
inhibitors. After 30 min on ice, insoluble material was pelleted
by centrifugation at 2000  g for 5 min at 4 °C. The protein
content of the soluble fractions was measured with a BCA pro-
tein assay kit according to the manufacturer’s instructions
(Thermo Scientific, Rockford, IL). The preparation of biotiny-
lated samples was performed as detailed previously (31).
Immunoprecipitation was carried out according to a modifi-
cation of a method described previously (31). Briefly, 100-l
aliquots of VSMC lysate precleared with protein G-Sepharose
were incubated with recombinant maspin (0, 1, or 5 g maspin
to 200 g of cellular protein) for 12 h at 4 °C. 5 g of anti-
maspin or anti-integrin was added, and a further incubation
performed for 12 h at 4 °C. 50 l of 50% (v/v) protein G-Sepha-
rosewas added to each sample, and immune complexes allowed
to bind for at least 1 h at 4 °C. The beadswerewashed four times
with lysis buffer, and adsorbedmaterial eluted in non-reducing
Laemmli sample buffer.
For Western and ligand blotting, samples separated by SDS-
PAGE on a 10% resolving gel were transferred to PVDF (poly-
vinylidene difluoride) membranes (Bio-Rad). Protein bands
were detected by incubation with the appropriate primary anti-
body followed by horseradish peroxidase (HRP)-conjugated
secondary antibodies (0.65 g/ml). Biotinylated samples were
visualized with HRP-conjugated streptavidin (0.1 g/ml). For
ligand blotting, the antibody incubations were preceded by an
incubation with 1 g/ml ligand: maspin or 51-Fc.
ImmunofluorescenceMicroscopy—Subconfluent monolayers
were fixedwith 4% formaldehyde, followed by blockingwith 1%
BSA (bovine serum albumin) (w/v)/PBS. Protein and antibody
incubations were performed in 1% BSA (w/v)/PBS for 30min at
37 °C; between steps samples were washed with 0.1% Tween 20
(v/v)/PBS. The concentrations of primary antibodies used are
given in the respective figure legends. Secondary antibody was
Alexa Fluor 488 goat anti-mouse IgG at 2 g/ml. Slides were
mounted with Vectashield mounting medium (Vector Labora-
tories, Burlingame, CA). Cells were visualized and images cap-
tured with a CCD upright microscope (Carl Zeiss Ltd, Hert-
fordshire, UK). The same exposure conditions were used for
all slides and images were analyzed using Axiovision 4.5 soft-
ware. To quantify 1 integrin in the experiments using con-
formation-specific antibodies, the mean fluorescence inten-
sity of outlined cells was measured using Andor iQ software
(Andor, Belfast, UK). The mean intensity was multiplied by
the total number of pixels to obtain the integrated intensity
and then divided by the area of the cell to calculate fluores-
cence intensity/m2.
Affinity Chromatography—A maspin affinity column was
made using a 1-ml HiTrapTM NHS HP column from GE
Healthcare (Amersham Biosciences). 1 mg of recombinant
maspin was coupled to the column according to the product
guidelines. A lysate prepared from 6  107 HT1080 cells was
applied to the column. After incubation for 15min at 25 °C, the
columnwas washed with PBS to remove unbound protein. Elu-
ates were collected by sequential application of 3 ml of PBS
containing 0.5 M NaCl, 3 ml PBS containing 1 M NaCl and 3 ml
of wash buffer (0.1 M sodium acetate pH 4.0, 0.5 M NaCl). Frac-
tions were collected (1 ml) and analyzed by SDS-PAGE and
Western blotting.
Plasmids and Transfection—The full-length maspin cDNA
was a gift fromDr.MargaretWorrall (Department of Biochem-
istry, University College Dublin, Ireland). The maspin coding
region was subcloned into the mammalian expression vector
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pcDNA3.2-V5 using theGateway system (Invitrogen) to gener-
ate a maspin plasmid referred to as pcDNA3.2-Maspin. Trans-
fection of CHO cells was performed using FuGENE 6 reagent
(Roche Applied Science) according to the manufacturer’s
instructions; optimized at 1 g of DNA per 2 105 cells.
CellMigration Assays—Cellmigrationwas determined using
time lapse video microscopy as detailed previously (7). Briefly,
24-well plates were coated with 5 g/ml fibronectin, collagen I
or laminin in PBS overnight at 4 °C.Wells blocked for 30min at
37 °C with 1% BSA (w/v)/PBS, prior to seeding cells at a density
of 7500 cells/ml/well. After 16 h, cells were put in serum-free
conditions. After 24 h, 100 nM recombinant maspin or 5 g/ml
function-blocking antibody was added as required, and cells
were placed in a humidified chamber (37 °C, 5% CO2) and
migration recorded by computerized time-lapse video micros-
copy with a CCD inverted microscope (Carl Zeiss Ltd). Images
were acquired every 10min for 17 h. 10 randomly selected cells
were tracked per movie, quantified using Axiovision software,
and migration expressed in m/h.
Taqman Real-time PCR—Total RNA was extracted from
subconfluent monolayers using the High Pure RNA Isolation
kit (Roche Applied Science) according to the manufacturer’s
instructions. For each sample, 1 g of total RNA was reverse-
transcribed using 10 g/ml random hexamers and superscript
II reverse transcriptase (Invitrogen, Paisley, UK) according to
the manufacturer’s instructions. Integrin expression was quan-
tified by use of specific primers designed for use with universal
library probes (Universal Probe Library Assay Design Centre,
Roche Applied Science). To control against amplification of
genomic DNA, primers spanned intron/exon boundaries. 18S
rRNA was used as a reference gene to normalize differences in
the amounts of total RNA. Taqman reactions were performed
using the 7500 Fast Real-Time PCR System (Applied Biosys-
tems, Warrington, UK), using the manufacturer’s protocol.
Each reaction was performed in 25 l and contained the equiv-
alent of 5 ng of reverse-transcribed RNA (1 ng RNA for 18S),
50% TaqManMaster Mix (Applied Biosystems). Results were
analyzed using the standard curve method.
Statistical Analysis—Data are presented as mean S.D. Sig-
nificance was judged using the Student’s t test.
RESULTS
Maspin Binds to the Surface of VSMC—We have previously
shown that maspin can dynamically regulate the migration of
VSMC, inhibiting migration at low concentrations and over a
short time scale (7). We hypothesized that this was due to the
binding of maspin to cell surface proteins involved in cell-ma-
trix interactions, with integrins being potential candidates. In
the present study we set out to identify maspin-binding cell
surface proteins, using VSMC cultured to generate two pheno-
typic states. A differentiated or contractile, non-migratory phe-
notype, and a de-differentiated, synthetic phenotype that both
migrates and proliferates and is thought to resemble cells
responding to vascular injury.
To investigate the binding of exogenous maspin to the sur-
face of VSMC, cells were incubated with varying concentra-
tions of recombinantmaspin, which was subsequently detected
by immunofluorescence microscopy using a maspin specific
antibody.Maspin was found to bind de-differentiated VSMC in
a concentration-dependent manner and displayed a punctate
pattern of staining on the cell surface (Fig. 1, panels a–e). By
contrast, differentiated VSMC displayed no binding of maspin
(Fig. 1, panels f–j).
FIGURE 1. Maspin binding to VSMC. Panels a–j, maspin binding to VSMC
detected by immunofluorescencemicroscopy. Purified recombinant maspin
(0nM) (panels aand f), 40nM (panels bandg), 80nM (panels candh), and250nM
(panels d and i) was incubated with either de-differentiated (panels a–e) or
differentiated (panels f–j) VSMC. Isotype-matched IgG (2 g/ml) controls are
shown for cells incubatedwith 250 nMmaspin (panels e and j). Anti-maspin (2
g/ml) was used for detection. Secondary antibodies were Alexa Fluor 488-
labeled (green), and nuclei were counterstained with DAPI (blue). k, ligand
blot analysis of maspin binding to VSMC proteins. Whole cell lysates of both
differentiated and de-differentiated VSMC were blotted onto PVDF mem-
branes, incubatedwith recombinantmaspin andprobedwith an anti-maspin
antibody. Control blots in the absence of maspin incubation are also shown.
l, quantitative real-time PCR (TaqMan) analysis of integrin gene expression in
VSMC. Relative expression levels are shown as a “heatmap” based on Ct val-
ues, ranging from undetectable expression (40 cycles), through very low
(35–39 cycles), low (30–34 cycles), moderate (25–29 cycles), high (20–24
cycles) to very high expression (20 cycles).m, Western blot analysis of inte-
grin expression in VSMC. Whole cell lysates of both differentiated and de-dif-
ferentiated VSMCwere blotted onto PVDFmembranes and probedwith anti-
integrin antibodies. Ligand blot formaspin binding is shown for comparison,
and GAPDH is used as a loading control (10 g of cellular protein per lane).
Maspin Binding to1 Integrins Inhibits Cell Migration
27714 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 40•OCTOBER 2, 2009
 at UNIV O
F EAST ANG
LIA, on January 14, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
To identify candidate maspin binding proteins we used
ligand or far Western blotting. Whole cell lysates were sepa-
rated by SDS-PAGE, and blots incubated with maspin, prior to
detection with a maspin specific antibody. VSMC of both phe-
notypes showed a similar pattern of maspin-binding proteins,
although the intensity of the bands detected varied (Fig. 1k).
Three major protein bands were observed at 35, 40, and 150
kDa. The intensity of the two lowermolecularweight bandswas
only slightly higher in the de-differentiated cells. However, the
150-kDa band showed a large increase under these conditions
and has a mobility consistent with an integrin subunit.
As a first step toward determining the role of integrins in
bindingmaspin, we characterized integrin expression inVSMC
by Taqman real time PCR (Fig. 1l), and those most highly
expressed confirmed at the protein level by Western blot (Fig.
1m). Comparing the levels of expression in the two VSMCphe-
notypes it could be seen that 3, 5, and 1 subunits were
up-regulated in de-differentiated VSMC, with little change in
v or3 subunits, raising the possibility that these integrins are
involved in the binding of maspin to the surface of VSMC.
31 and 51 Bind to a Maspin Affinity Chromatography
Column—To directly investigate the binding of maspin to
cellular proteins, we employed affinity chromatography
using maspin as a ligand. Primary VSMC presented limita-
tions regarding the large number of cells needed for these
experiments; therefore HT-1080 cells were used as an alterna-
tive source of material. We have previously shown that maspin
inhibits the migration of these cells (7), and they have a similar
integrin profile to VSMC (data not shown). HT-1080 cell
lysates were applied to the maspin affinity column and specific
binding and elution of integrin subunits determined by West-
ern blot. We found that the integrin subunits 3, 5, and 1
bound specifically to the maspin column, whereas v and 3
were only detected in the flow through (Fig. 2). This provides
direct evidence that that the 31 and 51 integrin het-
erodimers may be involved in the binding of maspin to the
surface of VSMC. Neither uPA and uPAR, which have been
implicated as maspin-binding proteins, nor endogenous
maspin bound to the affinity column.
VSMC 31 and 51 Coimmunoprecipitate with Maspin—
To give further support for the involvement of the 31 and
51 integrin heterodimers in the binding of maspin to the
surface of VSMC, we determined whether these proteins could
be coimmunoprecipitated. Proteins on the surface of de-differ-
entiated VSMC were labeled with biotin, and cell lysates incu-
bated with recombinant maspin, before immunoprecipitation
with a maspin antibody. Maspin was efficiently immunopre-
cipitated from both cell lysates and controls under these condi-
tions (Fig. 3a). First, streptavidin was used to visualize biotiny-
lated proteins associated withmaspin. Two specific bands at 50
and 150 kDa were detected, the latter coinciding with the
maspin-binding protein detected by ligand blot (Fig. 1k) and
precipitated at a low concentration of maspin. Western blot-
ting for 1 integrin confirmed the presence of this integrin
subunit in the coimmunoprecipitate with maspin and that it
had a mobility indistinguishable from the biotinylated pro-
tein (Fig. 3a).
To investigate the involvement of other integrin subunits,
similar experiments were performed on lysates of cells that
had not been modified by biotin and by immunoprecipita-
tion with integrin rather than maspin antibodies. Consistent
with the observations with biotinylated cells, the 1 integrin
antibody was able to coimmunoprecipitate maspin, and this
was observed in VSMC of both phenotypes (Fig. 3b). Using an
antibody to 5, bothmaspin and the 1 subunit could be coim-
munoprecipitated (Fig. 3c). Similarly, an antibody to 3 immu-
noprecipitated both maspin and the 1 subunit (Fig. 3d). How-
ever, antibodies to either v (Fig. 3e) or 3 (data not shown)
failed to coimmunoprecipitate maspin with the relevant inte-
grin. In differentiated VSMC maspin was not immunoprecipi-
tated by either3 or5 antibodies (data not shown),most likely
due to the lower levels of these integrin subunits under these
conditions. These data are therefore consistent with the obser-
vationsmade with themaspin affinity column, and suggest that
maspin interacts specifically with 31 and 51 on the sur-
face of de-differentiated VSMC.
Maspin Interacts with the Extracellular Domain of 51—
To demonstrate a direct interaction betweenmaspin and 51
we have made use of an 51-Fc fusion protein, containing the
entire extracellular part of the integrin heterodimer, using a
ligand blot approach. Maspin was run on SDS-PAGE, blotted,
incubatedwith51-Fc, and probedwith an antibody to the1
integrin subunit. Concentration-dependent binding of
51-Fc to immobilized maspin was detected as a band at 37
kDa, with a minor band at 75 kDa representing a dimerized
form that also bound the integrin (Fig. 4b). Reduction with di-
thiothreitol did not affect the interaction with the integrin as,
despite the presence of 8 cysteine residues,maspin has no disul-
fide bonds.
FIGURE 2.Maspin affinity chromatography.HT1080 cell lysate was applied
to a maspin affinity column, after incubation the column was washed exten-
sively with PBS to remove unbound protein (Washes). Specifically bound pro-
teinswere then eluted by sequential application of 3ml of PBS containing 0.5
M NaCl, 1.0 M NaCl, and acetate buffer pH 4.0, and collected as 1-ml fractions
(Elutions, labeled 1–3, respectively). 30 l of each fraction was separated by
SDS-PAGEprior toWesternblottingwithprimary antibodies to1 (10g/ml),
3 (10 g/ml), 3 (1:1000 antiserum), 5 (1:1000 antiserum), v (10 g/ml),
maspin (1 g/ml), uPA (10 g/ml), or uPAR (10 g/ml).
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When 51-Fc was blotted and incubated with maspin an
interaction was again detected, but only under non-reducing
conditions indicating that maintenance of the integrin ectodo-
main structure was essential for binding and making a nonspe-
cific interaction between maspin and 51-Fc unlikely. A
major band was observed at 150 kDa representing the 1 inte-
grin subunit, and a minor band at 250 kDa representing the
heterodimer. These data demonstrate that maspin interacts
specifically with the extracellular domain of 51 and that this
interaction likely involves the  chain.
Inhibition of CHOMigration byMaspin Requires the 5 Inte-
grin Subunit—To obtain direct evidence for the role of 51 in
the binding of maspin and its effects on cell migration, we have
made use of CHOcells either stably transfectedwith the human
5 subunit (32) or the B2 clonewhich is essentially5-null (33).
Maspin was found to bind specifically to 5CHO cells with a
punctate distribution (Fig. 5a), as previously observed on
VSMC. However, no binding of maspin to B2CHO cells was
detected (Fig. 5c), consistent with the presence of 51 being
sufficient for maspin binding to the cell surface.
To determine the effect of maspin binding to 51 on cell
migration using this model, migration of 5CHO and B2CHO
cells was assessed in the presence and absence of exogenously
added maspin (Fig. 5b). The addition of 100 nM maspin, previ-
ously determined as optimal (7), significantly reduced the
migration of 5CHO cells on both fibronectin and laminin, but
not on collagen. By contrast,maspin had no effect on themigra-
tion of B2CHOcells on any of the threematrices. Similar effects
were also observed with endogenously expressed maspin, as
transfection of 5CHO and B2CHO with wild-type maspin
FIGURE3.CoimmunoprecipitationofmaspinandVSMC integrins. Lysates
of differentiated and de-differentiated VSMC were incubated for 14 h at 4 °C
with recombinant maspin, and subsequently immunoprecipitated using
antibodies to either maspin or various integrin subunits. a, cell lysates were
incubated with 0, 1, or 5 g maspin per 200 g of cellular protein, samples
immunoprecipitated with anti-maspin goat mAb and Western blots per-
formed with anti-maspin mouse mAb, anti-1 mouse mAb. Cell surface pro-
teins were also biotinylated and detected by streptavidin after immunopre-
cipitation. b–e, lysates were incubated with 1 g of maspin (chosen as
optimal amount), samples immunoprecipitatedwith anti-integrin antibodies
to1 (b),5 (c),3 (d), orv (e), andWestern blots performedwith antibodies
to either maspin or various integrins, as indicated.
FIGURE 4. Interaction of purified maspin and 51-Fc fusion proteins.
a, recombinant maspin (10, 50, 100, and 250 pmol), in the presence or
absenceof reductionwithDTT,was runonSDS-PAGE, andblots subsequently
incubatedwith51-Fc fusion protein (1g/ml) and probedwith an anti-1
antibody. b, 51-Fc (5, 10, and 30 pmol), in the presence or absence of
reductionwithDTT,was run on SDS-PAGE, andblots subsequently incubated
withmaspin (1g/ml) and probedwith an anti-maspin antibody. Each panel
also shows control blots, in which incubation with either 51-Fc or maspin,
respectively, has been omitted.
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aused a significant reduction in the migration of 5CHO on
fibronectin and laminin, while having no effect on the migra-
tion of B2CHO (Fig. 5d). Unexpectedly, both cell types dis-
played a punctate, cell surface staining pattern when maspin
was endogenously expressed (Fig. 5c). As this was not observed
in the presence of exogenously addedmaspin, it is possible that
secreted maspin is primarily associated with the matrix under-
lying the cells, as has been previously observed (34), and there-
fore apparently unaffected by the presence or absence of 51.
Overall, these data demonstrate that maspin binds specifically
to 51 and that this is sufficient for maspin to exert its inhib-
itory effect on cell migration.
Maspin Binding to 51 on VSMC Alters Integrin Activation
Status—To begin to understand the mechanisms involved in
the effect of maspin on 51 function, we investigated
whether maspin influenced the activation state of 1 inte-
grins on VSMC using two conformation-dependent antibod-
ies in immunofluorescence microscopy. These antibodies,
12G10 (35) and mAb13 (36), preferentially recognize “active”
and “inactive” conformations of 1, respectively (37, 38). Total
1 integrin on the surface of VSMC, determined using a non-
conformation-dependent antibody, was unchanged in the pres-
ence ofmaspin both in terms of its cell surface distribution (Fig.
6, panels a and b), and its abundance, as determined by semi-
quantitative image analysis (Fig. 6k). However, using the con-
formation-dependent antibodies, clear differences in staining
intensities were observed in the absence and presence of
maspin. There was a5-fold reduc-
tion in the detection of the active
conformation of 1 (Fig. 6, panels c
andd), and thiswas accompanied by
a concomitant 5-fold increase in the
detection of the inactive conforma-
tion (Fig. 6, panels e and f). Similar
results were also obtained with a 5-
fold higher concentration ofmaspin
and when the incubation time was
increased to 24 h. Therefore, bind-
ing of maspin appears to result in a
redistribution of the balance bet-
ween active and inactive confor-
mations of 1 integrin, possibly as a
consequence of the direct binding of
maspin, leading to an overall reduc-
tion in 1 activity. Consistent with
this as the functional mechanism,
antibody-mediated blocking of 1
function led to a 40% inhibition of
VMSC migration (Fig. 6l), in con-
trast to which blocking of v3
function had no significant effect.
DISCUSSION
Maspin has been shown to influ-
ence many aspects of cell behavior,
including migration, invasion, pro-
liferation, and apoptosis. Although
these effects have been proposed to
involve both intracellular and extracellular activities of maspin,
themechanisms responsible for these activities remain unclear.
We have previously demonstrated that the inhibitory effect of
maspin on cell migration is an extracellular activity of maspin,
and furthermore that it does not involve protease inhibition by
maspin (7). These observations suggested that maspin may
exert its effect by acting as a ligand for cell surface receptors,
rather than acting as a classical serpin. Consistent with this
notion, we demonstrate here that maspin binds to cell surface
integrins, in particular 51, that this binding causes inactivat-
ing conformational changes in the integrin and leads to the
inhibitory effect of maspin on cell migration.
Our previous study focused on VSMC (7), the migration of
these cells being a major contributory factor in the develop-
ment of atherosclerosis and other fibroproliferative vascular
diseases. Here we find that these cells bind exogenously
added maspin, with a punctate pattern observed on the cell
surface. This binding was only observed on VSMC displaying
the de-differentiated or synthetic phenotype. In contrast to
the differentiated or contractile phenotype, these cells are
motile and resemble the cells present in fibroproliferative
vascular lesions. Using ligand blotting, maspin was found to
bind to a limited number of proteins in lysates of both cell
types. One of these proteins, with a molecular weight of 150
kDa, and subsequently demonstrated to be the 1 integrin
subunit, was detected almost exclusively in the de-differen-
FIGURE 5. 51-dependent inhibition of CHO cell migration. a, binding of exogenous maspin to 5CHO
and B2CHO cells detected by immunofluorescence microscopy. Cells were incubated in the absence or pres-
ence of maspin (40 nM) and binding detected and visualized as detailed in Fig. 1. Maspin binding to the cell
surface is detected asgreen andnuclei are counterstainedblue.b, effect of exogenousmaspin on themigration
of 5CHO and B2CHO cells on fibronectin (FN), laminin (LN), or collagen I (CNI) was determined by time-lapse
video microscopy over a period of 17 h. Experiments were performed both in the presence (closed bars) and
absence (open bars) of recombinantmaspin (100 nM). c, binding of endogenously expressedmaspin to5CHO
and B2CHO cells transfectedwith either pcDNA3.2 (mapsin) or pcDNA3.2-Maspin (maspin). d, migration of
5CHOandB2CHO cells transfectedwith pcDNA3.2 (open bars) or pcDNA3.2-Maspin (closed bars). Data shown
represent the means and S.E. of three independent experiments. *, p 0.05; **, p 0.005.
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tiated cells. Consistent with this observation, expression of
1 integrin was shown to be up-regulated on de-differentia-
tion of VSMC. Further evidence for the specific binding of
maspin to 1 integrin comes from the retention of this pro-
tein on a maspin affinity column, coimmunoprecipitation of
maspin and 1 integrin, and the binding of maspin to puri-
fied recombinant 51. Western blot analysis of cellular
proteins binding to maspin by affinity chromatography also
indentified 3 and 5 integrin subunits, both of which are
partners for the 1 subunit in integrin heterodimers. Both
31 and 51 are major integrins in VSMC. However,
v3, another major integrin in VSMC, did not bind to the
maspin affinity column as neither v or 3 subunits were
detected by Western blot. Therefore, maspin appears to be
capable of binding to multiple 1 integrins.
The role of maspin binding to 51 in the inhibition of cell
migration was demonstrated in a model system consisting of two
CHO cell lines; B2CHO which are essentially devoid of 5 and
5CHO stably transfected with the human 5 subunit. Maspin
had no effect on the migration of B2CHO cells on a variety of
extracellular matrix substrates, whereas the migration of 5CHO
cells on both fibronectin and laminin was inhibited by maspin.
This inhibition of migration was to a similar extent to that previ-
ously observed on VSMC (7), and was observed both when cells
were treated with exogenous maspin and when cells were trans-
fected with maspin. Attempts to directly demonstrate a role for
51 in the inhibition of VSMC
migration bymaspinwere unsuccess-
ful, as we were unable to efficiently
silence 5 expression in these cells.3
Integrins have complex roles in
regulating cell motility and migra-
tion. This involves direct engage-
ment of extracellular matrix ligands
to mediate cell adhesion, which
can be modulated by “inside-out”
signals to alter the affinity for
these ligands, and also to trans-
duce “outside-in” signals to the
cytoplasm. The effect of maspin on
VSMCmigration is rapid (7), which
is consistent with maspin having a
direct mechanism of action, rather
than a mechanism involving down-
stream signal transduction. Con-
sistent with this we found that
maspin led to a change in the activa-
tion status of 1 integrins in VSMC.
This activation status is dependent
on the conformation of the integrin
heterodimer (39, 40), which can be
detected by conformation-specific
monoclonal antibodies (35, 36). The
binding of maspin to 51 caused
an increase in the proportion of 1
integrin in the inactive, low ligand-
binding affinity conformation, with
a concomitant decrease in the
active, high ligand binding affinity conformation. The reduc-
tion in binding of the 12G10 antibody could possibly be due to
simple steric hindrance of antibody binding by maspin, rather
than any change in integrin conformation, but a conforma-
tional inactivation of the integrin is strongly supported by the
observed increase inmAb13 binding. Consistentwith this, anti-
body-mediated blocking of 1 integrin function also inhibited
VSMC migration. Therefore maspin binding to 51, and
potentially other 1 integrins, is likely to affect cell migration
directly, making this effect distinct from the previously
reported increased expression of integrins, including 51, in
breast cancer cells on prolonged treatment with maspin (26).
The observed inhibitory effect of maspin on the migration of
5CHO cells on laminin is perhaps surprising, as laminin is not
a ligand for 51 and no effect was observed with B2CHO cells
lacking 51. This makes it possible that maspin binding to
51 can also indirectly influence the behavior of other inte-
grins. This may also be related to the observation that B2CHO
appeared to bindmaspin when it was expressed by the cells but
not when it was added exogenously, despite these cells lacking
5 expression.
Despite the inhibitory effect of maspin on the migration of
both VSMC and 5CHO cells, we have found it to have no
3 R. Bass and V. Ellis, unpublished experiments.
FIGURE 6. Maspin alters 1 integrin conformation on VSMC. The cell surface expression of integrins on
VSMCwas determined in the absence (panels a, c, e, g, and i). and presence (panels b, d, f, h, and j) of incubation
with maspin (100 nM) for 1 h at 37 °C. Antibodies were to total 1 (1:50 dilution), active 1 (12G10, 5 g/ml),
inactive 1 (mAb13, 5 g/ml), v integrin (L230, 10 g/ml), and nonspecific IgG control (5 g/ml). Integrins
detected by Alexa Fluor 488 fluorescence (green) and nuclei are shown counterstained with DAPI (blue).
k, images taken from randomly chosen cell fields were analyzed for Alexa Fluor 488 staining intensity in four
independent experiments. Data are shown for total 1, active 1 (12G10) and inactive 1 (mAb13) in the
absence (open bars) and presence of maspin (closed bars). The intensity of v staining, used here as control
non-maspin-binding integrin, was unchanged. Data shown aremean S.D. (n 4). *, p 0.05; **, p 0.0005.
l, effect of function blocking antibodies on VSMCmigration. Cells were incubated with either anti-1 mAb13,
anti-v MAB1980, or control IgG (all at 5 g/ml) and migration assessed by time-lapse video microscopy (7).
Data shown are mean S.D. (n 3). *, p 0.01.
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significant effect on the adhesion of these cells to a variety of
extracellular matrix substrates.3 This is in contrast to the
maspin-induced increase in cell adhesion observed in other cell
types (26, 41–43). Whether these differences are cell-type
related or methodological is unresolved but, in support of our
conclusions here, one of these studies implicated 1 integrins
in the pro-adhesive effect asmaspin and1 integrin colocalised
on the cell surface and could be coimmunoprecipitated (43).
Maspin has previously been reported to bind to collagens I and
III (44). However we found that maspin had no effect on cell
migration on collagen, consistent with its specific interactions
with non-collagen-binding 51 and 31 integrins.
Maspin is considered to be primarily an intracellular serpin
that can also enter secretory vesicles (21), and there is consid-
erable controversy regarding its site of action. The inhibitory
effect of maspin on 5CHO cell migration was observed both
when purified maspin was added to the cells and when the cells
were transfected with maspin. As maspin was also observed to
bind to the cell surface, these effects must be due to an extra-
cellular activity of maspin. The interaction of maspin with the
purified recombinant 51-Fc is important in this respect, as it
demonstrates that maspin binds to the extracellular region of
the integrin rather than to the cytoplasmic tail, which is not
present in this fusion protein. Therefore, the integrin-mediated
effect of maspin is not dependent on an intracellular mecha-
nism involving an interaction between non-secreted maspin
and the intracellular tail of the integrin. The extracellular
regions of integrins are known to interact with a variety of pro-
teins, in addition to their principal extracellular matrix ligands.
These interactions can affect integrin function (45), and we
have demonstrated here that maspin can similarly act as an
integrin-associated protein.
Although our interest in maspin specifically relates to its
inhibitory effect on VSMC migration, the integrin-mediated
mechanism is not restricted to these cells as it is also observed
on CHO cells. Therefore, the binding of secreted, extracellular
maspin to1 integrinsmay be amore generalmechanism for its
biological effects, which include the inhibition of cancer cell
invasion and metastasis. In addition, the maspin knock-out is
embryonically lethal in mice, which has been attributed to an
impaired ability of endodermal cells to interact with their sur-
rounding extracellular matrix (42). The 1 integrin knock-out
displays very similar characteristics (46), and thus the defect in
maspin-null mice has been speculated to be due to maspin
interactions with 1 integrin (42).
How maspin interacts with 1 integrins has yet to be deter-
mined. It has been reported that the reactive center loop, cen-
tral to the function of protease inhibitory serpins, is involved in
the extracellular effects of maspin on cell adhesion and migra-
tion (4, 41, 47), as well as to its intracellular effects on apoptosis
(25, 48). However, we find that mutation of the reactive center
loop of maspin has no effect on its ability to inhibit cell migra-
tion.4 This suggests that maspin contains multiple functional
epitopes, a notion also supported by other studies (43, 44).
Another non-inhibitory serpin, pigment epithelium-derived
factor (SERPINF1),which displays neuroprotective, anti-angio-
genic and tumor suppressive activities has similarly been dem-
onstrated to affect these processes using different functional
epitopes, and by interacting with different putative receptors
(49–51). Identification of the structural epitope of maspin that
interacts with 1 integrins will lead to a further understand-
ing the activity of this multifunctional, but non-inhibitory,
serpin and inform further studies on potential maspin-based
therapeutics.
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